RBC Capital on Pliant Therapeutics (PLRX): 'we believe there was nothing concerning emerging from the call '

RBC Capital analyst Brian Abrahams reiterated an Outperform rating and $54.00 price target on Pliant Therapeutics (NASDAQ: PLRX)

The analyst comments "We highlight several tidbits emerging from the company's conference call this morning with more details from the ph.II '809 IPF study. In totality, we believe there was nothing concerning emerging from the call that would change our initial view that '809's efficacy is real and should be replicable in future studies in this large-market indication, and that there are no worrisome safety signals to date. We expect substantial continued appreciation for shares and remain buyers into strength."

For an analyst ratings summary and ratings history on Pliant Therapeutics click here. For more ratings news on Pliant Therapeutics click here.

Shares of Pliant Therapeutics closed at $8.88 yesterday.

You May Also Be Interested In

• Seaport Global Securities Starts ADI Global Distribution (ADIG) at Buy
• Celcuity Inc (CELC) PT Lowered to $150 at Stifel as Gedatolisib Distribution Initiated
• Yeti Holdings Inc. (YETI) PT Raised to $45 at Stifel on Beat and Raise Q2 Results